Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin
Covered in this story
Call it yourself
No calls on $PVLA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Palvella Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.